Loading stock data…
ELAB
$1.95-0.03 (-1.52%)
Market OpenUpdated 9:42 AM EDT
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PMGC Holdings Inc. in the Healthcare sector is trading at $1.95. The stock is currently near its 52-week low of $1.62, remaining 97.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 23) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$1.95
Potential Downside
0%
Whystock Fair Value$1.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to add...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-98.86%
Volume
Today's trading volume
165,029
Recent News
PMGC Grabs Precision Parts Maker Serving Boeing, Honeywell
Diversified holding company PMGC Holdings Inc. (NASDAQ:ELAB) shares rose in Wednesday premarket trading after a new acquisition announcement. PMGC acquired A&B Aerospace for $4.5 million, marking its fifth acquisition in the past 12 months. PMGC Expands Aerospace Manufacturing Platform PMGC acquired California-based A&B Aerospace, a precision-machining and aerospace manufacturing company serving the aerospace, defense, and industrial markets. A&B Aerospace was founded in 1948 and is headquartere
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened
US stocks looked set to open higher in Wednesday's trading session after President Trump claimed tha
BC-Most Active Stocks
Nu Holdings Ltd. 57,555,137 13.98
This Week In AI Chips - Reshoring Boosts Manufacturing Amid Strategic Partnerships and Acquisitions
Recent developments in the AI chip industry have underscored the strategic importance of precision manufacturing in supporting critical supply chains. PMGC Holdings Inc. recently completed the acquisition of AGA Precision Systems LLC, a California-based CNC machining company. This acquisition is part of a broader trend towards reshoring and strengthening domestic manufacturing capabilities, particularly for industries like aerospace and defense. As demand for high-tolerance and specialty...
Northstrive announces initiation of Phase II of AI Development Program
Northstrive Biosciences announced the initiation of Phase II of the AI Development Program with strategic partner Yuva Biosciences. As part of the Phase II objective, both companies will collaborate to leverage MitoNova, YuvaBio’s AI mitochondrial science-focused artificial intelligence platform, to compile a selection of small molecule candidates that promote mitochondrial health in obesity and cardiac diseases. YuvaBio will use MitoNova to virtually screen a large-scale library of diverse, dru